Clinical outcomes with ertapenem as a first-line treatment option of infections caused by extended-spectrum β-lactamase producing gram-negative bacteria;L'ertapénem utilisé comme agent de première intention dans le traitement des infections causées par les bactéries productrices de β-lactamase à spectre etendu

Annals of Pharmacotherapy

Volumn 46, Issue 3, 2012, Pages 347-352

  Fong, Jeffrey J ^a   Rosé, Lucia ^b   Radigan, Elizabeth A ^c  

^a UMASS MEMORIAL MEDICAL CENTER   (United States)

^b WESTERN NEW ENGLAND UNIVERSITY   (United States)

^c Memorial Medical Center   (United States)

Author keywords

Antimicrobial resistance; Ertapenem; ESBL; Extended spectrum lactamases; Gram negative infections; Hospital acquired infection

Indexed keywords

ERTAPENEM;

ADULT; ARTICLE; DRUG EFFICACY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING GRAM NEGATIVE BACTERIAL INFECTION; FEMALE; GRAM NEGATIVE INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BETA-LACTAMS; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; MALE; MIDDLE AGED;

EID: 84858066454     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1Q473     Document Type: Article

References (22)

1. Bradford PA. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance to threat. Clin Microbiol Rev 2001;14:933-51.
2. Jacoby GA, Munoz-Price LS. The new β-lactamases. N Engl J Med 2005;352:380-91.
3. Burgess DS, Hall RG, Lewis JS, Jorgensen JH, Patterson JE. Clinical and microbiological analysis of a hospital's extended spectrum beta-lactamase-producing isolates over a 2 year period. Pharmacotherapy 2003;23: 1232-7.
4. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Kleb-siella pneumoniae bacteremia: implications of production of extended spectrum beta-lactamases. Clin Infect Dis 2004;39:31-7.
5. Endimiani A, Luzzaro F, Perilli M, et al. Bacteremia due to Klebsiella pneumoniae isolates producing the TEM-52 extended spectrum beta lactamases: treatment outcome of patients receiving imipenem or ciprofloxacin. Clin Infect Dis 2004;38:243-51.
6. Keating GM, Perry CM. Ertapenem: a review of its use in the treatment of bacterial infections. Drugs 2005;65:2151-78.
7. Mody RM, Erwin DP, Summers AM, et al. Ertapenem susceptibility of extended-spectrum beta-lactamase-producing organisms. Ann Clin Microbiol Antimicrob 2007;6:6-10.
8. Behera B, Mathur P, Das A, Kapil A. Ertapenem susceptibility of extended spectrum β-lactamase-producing Enterobacteriaceae at a tertiary care centre in India. Singapore Med J 2009;50:628-32.
9. Teng CP, Chen HH, Chan J, Lye DC. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing gram-negative bacterial infections. Int J Antimicrob Agents 2007;30:356-9.
10. Berg ML, Crank CW, Philbrick AH, Hayden MK. Efficacy of ertapenem for consolidation therapy of extended-spectrum β-lactamase producing gram-negative infections: a case series report. Ann Pharmacother 2008; 42:207-12. DOI 10.1345/aph.1K365
11. Lye DC, Wijaya L, Chan J, Teng CP, Leo YS. Ertapenem for treatment of extended-spectrum beta-lactamase-producing and multidrug-resistant gram-negative bacteraemia. Ann Acad Med Singapore 2008;37:831-4.
12. Hernandez JR, Romero L, Velasco C, Martinez-Martinez L, Pascual A. Comparative in vitro activity of ertapenem against ESBL-producing E. coli and K. pneumoniae isolated in Spain. Int J Antimicrob Agents 2006; 28:457-9.
13. Allhambra A, Cuadros JA, Cacho J, Gomez-Garces L, Alos JI. In vitro susceptibility of recent antibiotic-resistant urinary pathogens to ertapenem and 12 other antibiotics. J Antimicrob Chemother 2004;53:1090-4.
14. Paterson DL, Rossi F, Baquero F, et al. In vitro susceptibilities of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: the 2003 study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother 2005;55:965-73.
15. Gaieski DF, Mikkelsen ME, Band RA, et al. Impact of time to antibiotics on survival in patients with severe sepsis or septic shock in whom early goal directed therapy was initiated in the emergency department. Crit Care Med 2010;38:1045-53.
16. Bassetti M, Righi E, Fasce R, et al. Efficacy of ertapenem in the treatment of early ventilator-associated pneumonia caused by extended-spectrum β-lactamase-producing organisms in the intensive care unit. J Antimicrob Chemother 2007;60:433-5.
17. Gupta K, Hooton TM, Naber KG, et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011;52:e103-20.
18. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006;42:S164-72.
19. Sobel JD, Kaye D. Urinary tract infections. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier, 2010:957-85.
20. Wong-Beringer A. Therapeutic challenges associated with extended spectrum beta lactamases-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001;21:583-92.
21. Ahmad M, Urban C, Mariano N, et al. Clinical characteristics and molecular epidemiology associated with imipenem-resistant Klebsiella pneumoniae. Clin Infect Dis 1999;29:352-5.
22. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994;344:1329-32.